GS
RXRX icon

GTS Securities’s Recursion Pharmaceuticals RXRX Stock Holding History

GTS Securities’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105K Buy
+34,174
New +$132K ﹤0.01% 1423
2025
Q4 		– Sell
-52,557
Closed -$256K – 1729
2025
Q3 		$256K Buy
+52,557
New +$276K 0.01% 1138
2023
Q4 		– Sell
-10,476
Closed -$80.1K – 4362
2023
Q3 		$80.1K Buy
+10,476
New +$105K ﹤0.01% 3637

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GTS Securities's RXRX Position: Q1 2026 in Review

GTS Securities opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 34,174 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #1423 among its holdings. This is a return to the name: GTS Securities previously reported a position in RXRX as recently as Q3 2025.

GTS Securities first reported a position in RXRX in Q3 2023 and has held it in 3 quarters since. The position peaked at $256K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • GTS Securities held 34,174 shares of Recursion Pharmaceuticals worth $105K as of Q1 2026.
  • Recursion Pharmaceuticals was a new GTS Securities position in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of GTS Securities's portfolio in Q1 2026, its #1423 holding.
  • GTS Securities first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 3 quarters since.
  • GTS Securities's Recursion Pharmaceuticals position peaked at $256K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.